TrialEmerging microbes & infections2024

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.

Chunhua Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.